19/10/2026
Behind every rare disease is a person, a family, and a search for answers.
For many rare diseases, effective treatment remains out of reach. The FDA’s new Rare Disease Framework Initiative aims to address challenges in developing and reviewing treatments, while giving greater consideration to patient and caregiver experiences.
The conversation is open to the rare disease community.
The FDA is holding a public meeting on October 28, 2026, to gather input on the initiative. Patients, caregivers, researchers, and advocacy organisations can follow the discussion and contribute their perspectives.
Every perspective can help inform how rare disease treatments are developed in the future.
🔗 Learn more about the initiative and public meeting.
Link in the comments.